BNC210 Amorphous Solid Dispersions for Oral Exposure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of non-sedative anxiolytic APIs face challenges such as high melting point, poor in vitro solubility, low oral exposure, and significant food effect, leading to undesirable drug interactions and crystallization issues.
Innovation Solution
A solid dispersion formulation comprising a compound of formula (I) dispersed within a polymer matrix, specifically using a crystallization inhibitor polymer in a ratio of 10:90 to 80:20 wt/wt%, which is prepared via spray drying or hot melt extrusion, to maintain the compound in an amorphous form and enhance solubility and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If the compound is formulated in conventional forms, then the formulation is simple to manufacture, but the compound exhibits poor in vitro solubility and low oral exposure
Solution Approach 1:
The patent changes the physical state of the compound from crystalline to amorphous form, and incorporates it into a polymer matrix (solid dispersion) to fundamentally alter its dissolution and absorption characteristics, thereby achieving reliable oral exposure
Solution Approach 2:
The patent creates a composite material system consisting of the compound dispersed within a polymer matrix (e.g., HPMC, Eudragit). This composite structure provides both the therapeutic activity of the compound and the solubility-enhancing properties of the polymer, achieving reliable oral exposure while remaining manufacturable
2Adaptability or versatility
If the compound is administered under fed conditions, then food effect studies can be conducted, but the compound shows significant food effect and variable absorption
Solution Approach 1:
The patent changes the physical form of the compound to amorphous solid dispersion, which dramatically improves solubility and dissolution rate. This parameter change reduces the variability in absorption whether the drug is taken with food or on an empty stomach, achieving consistent bioavailability across different fed/fasted conditions
3Reliability
If the compound is stored in amorphous form, then solubility and dissolution are improved, but crystallization may occur reducing stability
Solution Approach 1:
The patent uses a polymer matrix (such as HPMC, Eudragit, or other excipients) as an intermediary substance that physically surrounds and stabilizes the amorphous compound molecules. This polymer barrier prevents the compound molecules from organizing into crystalline structures, thereby maintaining both high solubility and long-term stability
Solution Approach 2:
The patent creates a composite material where the amorphous compound is dispersed within a stabilizing polymer matrix. This composite structure provides both the desired solubility enhancement of the amorphous form and the crystallization resistance of the polymer, achieving both improved solubility and compositional stability simultaneously
4Quantity of substance
If high loading of API is achieved in tablets, then therapeutic efficacy is improved, but crystallization and food effect increase
Solution Approach 1:
The patent changes the physical state of the API from crystalline to amorphous and incorporates it into a polymer matrix, enabling high API loading (up to 50% or more by weight) while preventing crystallization. The amorphous dispersion in polymer provides both high loading capacity and crystallization resistance
Solution Approach 2:
The polymer matrix acts as an intermediary that allows high concentrations of API to be incorporated into the tablet without causing crystallization. The polymer molecules physically separate and stabilize the API molecules, preventing them from organizing into crystalline structures even at high loadings
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves high loading of the API in tablets, minimizing crystallization and food effect, ensuring rapid dissolution and effective therapeutic plasma concentration for up to 24 hours, with reduced sedative side effects.
Implementation Method 1
dispersed within a polymer matrix formed by at least one pharmaceutically acceptable polymer... to maintain the compound in an amorphous form
Implementation Method 2
A solid dispersion formulation comprising a compound of formula (I) dispersed within a polymer matrix
Implementation Method 3
specifically using a crystallization inhibitor polymer in a ratio of 10:90 to 80:20 wt/wt%, which is prepared via spray drying or hot melt extrusion, to maintain the compound in an amorphous form and enhance solubility and stability
Data Source
AI summary
This invention relates to formulations of compound (I) (BNC210), an allosteric modulator of the α7-nicotinic receptor with non-sedative anxiolytic effects; specifically, solid dispersions, methods of manufacture thereof, and therapeutic methods and uses in the treatment of diseases of the central nervous system thereof.